RT Journal Article
SR Electronic
T1 COVID-19 Vaccine Effectiveness against Symptomatic and Asymptomatic SARS-CoV-2 Infections with the Delta Variant among a Cohort of Children Aged ≥ 12 Years and Adults in Utah
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.13.22281012
DO 10.1101/2022.10.13.22281012
A1 Mohanty, Sarita
A1 Dawood, Fatimah S.
A1 Stanford, Joseph B.
A1 Duque, Jazmin
A1 Stockwell, Melissa S.
A1 Veguilla, Vic
A1 Porucznik, Christina A.
YR 2022
UL http://medrxiv.org/content/early/2022/10/17/2022.10.13.22281012.1.abstract
AB We conducted weekly surveillance for SARS-CoV-2 infection among a sample of households with ≥1 child aged 0-17 years from selected Utah counties. A Cox proportional hazards model approach was used to calculate infection hazard rate and vaccine effectiveness. Findings show that the recommended primary series of COVID-19 vaccine was effective against circulating variants during a Delta-predominant wave in Utah.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCDC funded this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the University of Utah Institutional Review Board (IRB) which served as the central IRB for all study collaboratorsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors